

Results of 2023 Annual General Meeting

Melbourne, Australia; 29 November 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces the details of the resolutions and the proxies and votes received in respect of each resolution at its Annual General Meeting (AGM) held today in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, as set out in the attached proxy and voting summary.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As an innovative Australian biopharmaceutical company, Starpharma is focused on developing and commercialising novel therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products, partnerships, and intellectual property.

Starpharma's innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.

Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma's portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced Product ("DEP[®]") drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel[®] BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties.

Starpharma's DEP[®] drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery. In addition to Starpharma's internal DEP[®] programs, Starpharma has multiple DEP[®] partnerships with international biopharmaceutical companies, including AstraZeneca (oncology), MSD (Antibody-Drug Conjugates), Chase Sun (anti-infectives), and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma's DEP[®] platform, partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

Starpharma's topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries*, including Europe, the UK, and Asia. Starpharma's novel non-antibiotic vaginal gel, VivaGel[®] BV, for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and New Zealand.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](https://www.linkedin.com/company/starpharma).

WE Communications

Hannah Howlett
+61450 648 064
WE-AUStarPharma@we-worldwide.com

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Company Secretary, Mr Justin Cahill.

Forward-Looking Statements

This document contains certain forward-looking statements relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", "outlook", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of any Starpharma product.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	135,187,477 77.92%	36,516,882 21.04%	1,812,811 1.04%	1,681,686	142,368,893 78.95%	37,967,669 21.05%	2,081,686	Carried
2 Election of Board endorsed Director, Dr Russell Basser	Ordinary	171,063,635 95.09%	7,015,577 3.90%	1,812,461 1.01%	298,723	179,585,800 96.03%	7,416,154 3.97%	754,786	Carried
3 Re-Election of Mr Robert B Thomas AO	Ordinary	133,689,641 83.73%	24,152,057 15.13%	1,812,461 1.14%	20,536,237	140,976,596 84.43%	26,002,844 15.57%	20,777,300	Carried
4 Re-Election of Mr David McIntyre	Ordinary	166,723,569 92.79%	11,065,056 6.16%	1,892,461 1.05%	509,310	175,325,734 93.96%	11,265,633 6.04%	1,165,373	Carried
5 Approval of Starpharma Holdings Limited Employee Performance Rights Plan	Ordinary	125,292,044 71.35%	47,052,020 26.79%	3,274,674 1.86%	530,118	134,215,597 73.48%	48,432,533 26.52%	1,067,070	Carried
6 Approval of issue of Performance Rights to Dr Jacinth Fairley	Ordinary	123,327,398 70.18%	49,139,627 27.96%	3,274,674 1.86%	4,407,591	132,080,677 72.15%	50,990,414 27.85%	4,644,543	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only